These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 17199159)
1. [New drugs in the treatment of noninfectious uveitis]. Cano-Parra J; Díaz-Llopis M Arch Soc Esp Oftalmol; 2006 Dec; 81(12):671-3. PubMed ID: 17199159 [No Abstract] [Full Text] [Related]
2. [Intraocular pressure elevation after subtenon injection of triamcinolone acetonide during uveitis]. Bui Quoc E; Bodaghi B; Adam R; Burtin T; Cassoux N; Dreifuss S; Fardeau C; LeHoang P J Fr Ophtalmol; 2002 Dec; 25(10):1048-56. PubMed ID: 12527830 [TBL] [Abstract][Full Text] [Related]
3. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. Arcinue CA; Cerón OM; Foster CS J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752 [TBL] [Abstract][Full Text] [Related]
4. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854 [TBL] [Abstract][Full Text] [Related]
5. The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis. Demir T; Gödekmerdan A; Balbaba M; Türkçüoglu P; Ilhan F; Demir N Indian J Ophthalmol; 2006 Dec; 54(4):241-5. PubMed ID: 17090875 [TBL] [Abstract][Full Text] [Related]
7. [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases]. Jonas JB; Kreissig I; Kamppeter B; Degenring RF Ophthalmologe; 2004 Feb; 101(2):113-20. PubMed ID: 14991306 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Bollinger KE; Smith SD Curr Opin Ophthalmol; 2009 Mar; 20(2):99-103. PubMed ID: 19248312 [TBL] [Abstract][Full Text] [Related]
9. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Pulido JS; Pulido JE; Michet CJ; Vile RG Retina; 2010 Jan; 30(1):1-5. PubMed ID: 20061905 [No Abstract] [Full Text] [Related]
11. The use of intraocular corticosteroids. Kiernan DF; Mieler WF Expert Opin Pharmacother; 2009 Oct; 10(15):2511-25. PubMed ID: 19761356 [TBL] [Abstract][Full Text] [Related]
12. Which way forward for treatment of severe ocular inflammation? Lightman S; McCluskey PJ Clin Exp Ophthalmol; 2006; 34(4):293-4. PubMed ID: 16764644 [No Abstract] [Full Text] [Related]
13. Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Lasave AF; Zeballos DG; El-Haig WM; Díaz-Llopis M; Salom D; Arevalo JF Ocul Immunol Inflamm; 2009; 17(6):423-30. PubMed ID: 20001264 [TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of children with uveitis treated with infliximab. Tugal-Tutkun I; Ayranci O; Kasapcopur O; Kir N J AAPOS; 2008 Dec; 12(6):611-3. PubMed ID: 18930672 [TBL] [Abstract][Full Text] [Related]
16. Treatment of persistent glaucoma secondary to periocular corticosteroids. Akduman L; Kolker AE; Black DL; Del Priore LV; Kaplan HJ Am J Ophthalmol; 1996 Aug; 122(2):275-7. PubMed ID: 8694104 [TBL] [Abstract][Full Text] [Related]
17. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625 [TBL] [Abstract][Full Text] [Related]
18. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830 [TBL] [Abstract][Full Text] [Related]
19. Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis. Roesel M; Gutfleisch M; Heinz C; Heimes B; Zurek-Imhoff B; Heiligenhaus A Eye (Lond); 2009 Apr; 23(4):910-4. PubMed ID: 18464803 [TBL] [Abstract][Full Text] [Related]
20. Comparison of intravitreal injection of bevacizumab and triamcinolone acetonide in the treatment of uveitic macular edema. Rahimi M; Shahrzad SS; Banifatemi M Iran J Immunol; 2012 Jun; 9(2):136-44. PubMed ID: 22735801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]